Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextromethorphan + phenylpropanolamine + pheniramine is a fixed-dose combination pharmaceutical product manufactured by Chemidrug Industries in Nepal. It is indicated for the symptomatic relief of cough and cold symptoms. The combination consists of three active ingredients: dextromethorphan, a centrally acting antitussive that suppresses the cough reflex by elevating the cough threshold; phenylpropanolamine, a sympathomimetic decongestant that reduces nasal congestion by constricting blood vessels in the nasal passages; and pheniramine, a first-generation antihistamine that alleviates allergic symptoms such as sneezing and rhinorrhea. This product is marketed as a generic cough preparation in the Nepalese market, where these active ingredients remain approved for clinical use despite phenylpropanolamine being withdrawn in several other global jurisdictions due to safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + phenylpropanolamine + pheniramine.